Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNASE1L3 | Q13609 | 1/20 | 1.00 |
| ▸ | PRMT1 | Q99873 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | ALPG | P10696 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 16/20 | 0.51 |
| ▸ | CA1 | P00915 | 14/20 | 0.51 |
| ▸ | CA2 | P00918 | 14/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PLEC | Q15149 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412907 | 1.00 | DNASE1L3 (1.00) | DNASE1L3PRMT1USP2L3MBTL1MEN1 | |
| SCHEMBL12842816 | 0.94 | DNASE1L3 (0.88) | DNASE1L3PRMT1USP2L3MBTL1MEN1 | |
| SCHEMBL30563616 | 0.83 | DNASE1L3 (0.71) | DNASE1L3PRMT1USP2L3MBTL1MEN1 | |
| SCHEMBL17243936 | 0.82 | DNASE1L3 (0.70) | DNASE1L3PRMT1USP2L3MBTL1MEN1 | |
| SCHEMBL17974475 | 0.81 | DNASE1L3 (0.68) | DNASE1L3PRMT1USP2L3MBTL1MEN1 | |
| SCHEMBL17974603 | 0.80 | DNASE1L3 (0.66) | DNASE1L3PRMT1USP2L3MBTL1MEN1 | |
| SCHEMBL24454976 | 0.79 | DNASE1L3 (0.65) | DNASE1L3PRMT1USP2L3MBTL1MEN1 | |
| SCHEMBL17971015 | 0.79 | DNASE1L3 (0.65) | DNASE1L3PRMT1USP2L3MBTL1MEN1 | |
| SCHEMBL609275 | 0.79 | DNASE1L3 (0.65) | DNASE1L3PRMT1USP2L3MBTL1MEN1 | |
| 6-Carboxyfluorescein SCHEMBL9906208 | 0.79 | USP2 (0.69) | DNASE1L3PRMT1USP2L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230332256-A1 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | UNIV JOHNS HOPKINS (US) | 2023-10-19 | — | — | US | claimed |
| US-20230241015-A1 | CANCER THERAPEUTIC COMPOSITIONS AND METHODS TARGETING DNASE1L3 | PROVIDENCE HEALTH & SERVICES - OREGON (US) | 2023-08-03 | — | — | US | claimed |
| WO-2022067032-A9 | CANCER THERAPEUTIC COMPOSITIONS AND METHODS TARGETING DNASE1L3 | PROVIDENCE HEALTH & SERVICES - OREGON (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2022067032-A1 | CANCER THERAPEUTIC COMPOSITIONS AND METHODS TARGETING DNASE1L3 | PROVIDENCE HEALTH & SERVICES - OREGON (US) | 2022-03-31 | — | — | WO | claimed |
| WO-2022061172-A2 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | claimed |
| US-12336973-B2 | Cancer therapeutic compositions and methods targeting DNAse1L3 | PROVIDENCE HEALTH & SERVICES—OREGON (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250163162-A1 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRING | SYNTHEKINE, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4274616-A2 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRING | Synthekine, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230332256-A1 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | UNIV JOHNS HOPKINS (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230241015-A1 | CANCER THERAPEUTIC COMPOSITIONS AND METHODS TARGETING DNASE1L3 | PROVIDENCE HEALTH & SERVICES - OREGON (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2022150788-A2 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRING | SYNTHEKINE, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022067032-A9 | CANCER THERAPEUTIC COMPOSITIONS AND METHODS TARGETING DNASE1L3 | PROVIDENCE HEALTH & SERVICES - OREGON (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022067032-A1 | CANCER THERAPEUTIC COMPOSITIONS AND METHODS TARGETING DNASE1L3 | PROVIDENCE HEALTH & SERVICES - OREGON (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022061172-A2 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | disclosed |
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | NOVARTIS AG (CH) | 2019-11-19 | — | — | US | disclosed |
| US-20180010132-A1 | INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES | NOVARTIS AG (CH) | 2018-01-11 | — | — | US | disclosed |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20060070135-A1 | Compositions and methods for inhibiting the enzymatic activity of PTP-1B | TREMBLAY MICHEL | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | PRMT5, PRMT1, PRMT3 | DNASE1L3 1201/4885PRMT1 2/4885USP2 933/4885 |
| US-20180010132-A1 | INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES | PRMT5, PRMT1, PRMT6 | DNASE1L3 808/4885PRMT1 2/4885USP2 2270/4885 |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | PRMT5, PRMT1, PRMT3 | DNASE1L3 1201/4885PRMT1 2/4885USP2 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.